

# John R Kirwan

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5562431/john-r-kirwan-publications-by-citations.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

78 papers	4,223 citations	31 h-index	64 g-index
89 ext. papers	4,747 ext. citations	5 avg, IF	5.27 L-index

#	Paper	IF	Citations
78	The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. <i>New England Journal of Medicine</i> , <b>1995</b> , 333, 142-6	59.2	631
77	Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. <i>Journal of Clinical Epidemiology</i> , <b>2014</b> , 67, 745-53	5.7	508
76	Patients and professionals as research partners: challenges, practicalities, and benefits. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 55, 676-80		180
75	Articular indices of joint inflammation in rheumatoid arthritis. Correlation with the acute-phase response. <i>Arthritis and Rheumatism</i> , <b>1987</b> , 30, 618-23		155
74	Incorporating the patient perspective into outcome assessment in rheumatoid arthritis--progress at OMERACT 7. <i>Journal of Rheumatology</i> , <b>2005</b> , 32, 2250-6	4.1	149
73	Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 204-10	2.4	125
72	Outcomes from the Patient Perspective Workshop at OMERACT 6. <i>Journal of Rheumatology</i> , <b>2003</b> , 30, 868-72	4.1	122
71	Effects of glucocorticoids on radiological progression in rheumatoid arthritis. <i>The Cochrane Library</i> , <b>2007</b> , CD006356	5.2	118
70	Measuring fatigue in rheumatoid arthritis: a cross-sectional study to evaluate the Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional questionnaire, visual analog scales, and numerical rating scales. <i>Arthritis Care and Research</i> , <b>2010</b> , 62, 1559-68	4.7	111
69	Non-pharmacological interventions for fatigue in rheumatoid arthritis. <i>The Cochrane Library</i> , <b>2013</b> , CD008322	5.3	97
68	Systematic review of rheumatoid arthritis patient education. <i>Arthritis and Rheumatism</i> , <b>2004</b> , 51, 1045-59		89
67	Emerging Guidelines for Patient Engagement in Research. <i>Value in Health</i> , <b>2017</b> , 20, 481-486	3.3	88
66	Outcomes generated by patients with rheumatoid arthritis: how important are they?. <i>Musculoskeletal Care</i> , <b>2005</b> , 3, 131-42	1.6	86
65	Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial. <i>Archives of Internal Medicine</i> , <b>2005</b> , 165, 1293-7		84
64	Collaboration with patients in the design of patient-reported outcome measures: capturing the experience of fatigue in rheumatoid arthritis. <i>Arthritis Care and Research</i> , <b>2010</b> , 62, 1552-8	4.7	74
63	Patient education for adults with rheumatoid arthritis. <i>The Cochrane Library</i> , <b>2003</b> ,	5.2	67
62	The patient perspective on remission in rheumatoid arthritis: You've got limits, but you're back to being you again. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1004-10	2.4	62

61	Updating the OMERACT filter: implications for patient-reported outcomes. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 1011-5	4.1	48
60	Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients. <i>Rheumatology</i> , <b>2017</b> , 56, 1573-1578	3.9	47
59	Glucocorticoids: action and new therapeutic insights in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , <b>2007</b> , 19, 233-7	5.3	40
58	Effect of novel therapeutic glucocorticoids on circadian rhythms of hormones and cytokines in rheumatoid arthritis. <i>Annals of the New York Academy of Sciences</i> , <b>2010</b> , 1193, 127-33	6.5	38
57	Recommendations for the Involvement of Patient Research Partners (PRP) in OMERACT Working Groups. A Report from the OMERACT 2014 Working Group on PRP. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 187-93	4.1	37
56	Rheumatoid Arthritis: Disease-modifying Antirheumatic Drugs. <i>Clinics in Rheumatic Diseases</i> , <b>1983</b> , 9, 581-599		37
55	Biologic interventions for fatigue in rheumatoid arthritis. <i>The Cochrane Library</i> , <b>2016</b> , CD008334	5.2	37
54	The effect of therapeutic glucocorticoids on the adrenal response in a randomized controlled trial in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 1415-21		35
53	Reliability and sensitivity to change of the Bristol Rheumatoid Arthritis Fatigue scales. <i>Rheumatology</i> , <b>2013</b> , 52, 1832-9	3.9	32
52	Patient perspective on outcomes in rheumatology -- a position paper for OMERACT 9. <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 2067-70	4.1	32
51	Stiffness is more than just duration and severity: a qualitative exploration in people with rheumatoid arthritis. <i>Rheumatology</i> , <b>2015</b> , 54, 615-22	3.9	31
50	Successful Stepwise Development of Patient Research Partnership: 14 Years Experience of Actions and Consequences in Outcome Measures in Rheumatology (OMERACT). <i>Patient</i> , <b>2017</b> , 10, 141-152	3.7	31
49	Progress on incorporating the patient perspective in outcome assessment in rheumatology and the emergence of life impact measures at OMERACT 9. <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 2071-6	4.1	31
48	Reducing arthritis fatigue impact: two-year randomised controlled trial of cognitive behavioural approaches by rheumatology teams (RAFT). <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 465-472	2.4	28
47	Progress since OMERACT 6 on including patient perspective in rheumatoid arthritis outcome assessment. <i>Journal of Rheumatology</i> , <b>2005</b> , 32, 2246-9	4.1	28
46	Alleviation of morning joint stiffness by low-dose prednisone in rheumatoid arthritis is associated with circadian changes in IL-6 and cortisol. <i>International Journal of Clinical Rheumatology</i> , <b>2011</b> , 6, 241-249	1.5	25
45	Clinical and psychological outcomes of patient education in rheumatoid arthritis. <i>Musculoskeletal Care</i> , <b>2005</b> , 3, 1-16	1.6	25
44	Sensitivity to change of the Rheumatoid Arthritis Self-Efficacy scale (RASE) and predictors of change in self-efficacy. <i>Musculoskeletal Care</i> , <b>2008</b> , 6, 49-67	1.6	23

43	Low-dose glucocorticoid therapy in rheumatoid arthritis: an obligatory therapy. <i>Annals of the New York Academy of Sciences</i> , <b>2010</b> , 1193, 123-6	6.5	21
42	The risks of local and systemic corticosteroid administration. <i>Baillieres Clinical Rheumatology</i> , <b>1990</b> , 4, 305-32		21
41	Updating the OMERACT filter: core areas as a basis for defining core outcome sets. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 994-9	4.1	19
40	"An impediment to living life": why and how should we measure stiffness in polymyalgia rheumatica?. <i>PLoS ONE</i> , <b>2015</b> , 10, e0126758	3.7	19
39	"You Obviously Just Have to Put on a Brave Face": A Qualitative Study of the Experiences and Coping Styles of Men With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 330-337	4.7	18
38	Remission in Rheumatoid Arthritis: Working Toward Incorporation of the Patient Perspective at OMERACT 12. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 203-7	4.1	18
37	Measuring sensation in the feet of patients with rheumatoid arthritis. <i>Musculoskeletal Care</i> , <b>2006</b> , 4, 12-23		18
36	Men, rheumatoid arthritis, psychosocial impact and self-management: A narrative review. <i>Journal of Health Psychology</i> , <b>2016</b> , 21, 2168-82	3.1	17
35	Updating the OMERACT filter at OMERACT 11. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 975-7	4.1	17
34	Patient perspective: choosing or developing instruments. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 1716-9	4.1	17
33	Everyone assumes a man to be quite strong: Men, masculinity and rheumatoid arthritis: A case-study approach. <i>Sociology of Health and Illness</i> , <b>2018</b> , 40, 115-129	3	16
32	Systemic low-dose glucocorticoid treatment in rheumatoid arthritis. <i>Rheumatic Disease Clinics of North America</i> , <b>2001</b> , 27, 389-403, ix-x	2.4	15
31	Patient education in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , <b>1990</b> , 2, 336-9	5.3	14
30	Translating patient reported outcome measures: methodological issues explored using cognitive interviewing with three rheumatoid arthritis measures in six European languages. <i>Rheumatology</i> , <b>2016</b> , 55, 1009-16	3.9	11
29	Outcome Measures in Polymyalgia Rheumatica. A Systematic Review. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 2503-11	4.1	10
28	Symptom control with low-dose glucocorticoid therapy for rheumatoid arthritis. <i>Rheumatology</i> , <b>2012</b> , 51 Suppl 4, iv14-20	3.9	10
27	Stiffness Is the Cardinal Symptom of Inflammatory Musculoskeletal Diseases, Yet Still Variably Measured: Report from the OMERACT 2016 Stiffness Special Interest Group. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 1904-1910	4.1	9
26	Physical activity interventions for fatigue in rheumatoid arthritis: a systematic review. <i>Physical Therapy Reviews</i> , <b>2017</b> , 22, 12-22	0.7	8

25	Corticosteroid therapy in rheumatoid arthritis. <i>Baillieres Clinical Rheumatology</i> , <b>1990</b> , 4, 621-47		8
24	Group cognitive-behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations. <i>Health Technology Assessment</i> , <b>2019</b> , 23, 1-130	4.4	7
23	Coping Strategies, Psychological Impact, and Support Preferences of Men With Rheumatoid Arthritis: A Multicenter Survey. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 851-860	4.7	6
22	Biological treatment in rheumatoid arthritis: when to stop?. <i>Lancet, The</i> , <b>2014</b> , 383, 288-9	4.0	6
21	Efficacy, safety and mechanism of action of modified-release prednisone in rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2012</b> , 4, 159-66	3.8	6
20	Reporting of significance levels versus Pearson's correlation coefficient. <i>Rheumatology</i> , <b>1984</b> , 23, 232-3	3.9	6
19	Developing a group intervention to manage fatigue in rheumatoid arthritis through modifying physical activity. <i>BMC Musculoskeletal Disorders</i> , <b>2019</b> , 20, 194	2.8	5
18	The Spirit of OMERACT: Q Methodology Analysis of Conference Characteristics Valued by Delegates. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 1982-1992	4.1	5
17	The analysis of a bivariate multi-state Markov transition model for rheumatoid arthritis with an incomplete disease history. <i>Statistics in Medicine</i> , <b>1999</b> , 18, 1677-90	2.3	5
16	Identifying different typologies of experiences and coping strategies in men with rheumatoid arthritis: a Q-methodology study. <i>BMJ Open</i> , <b>2016</b> , 6, e012051	3	5
15	The benefit of low-dose glucocorticoid treatment in early rheumatoid arthritis may outweigh the risk: comment on the editorial by Harris. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 2031-2; author reply 2032		4
14	New modes of practice. <i>Current Opinion in Rheumatology</i> , <b>2004</b> , 16, 125-9	5.3	4
13	Development and validation of novel biomarker assays for osteoarthritis. <i>PLoS ONE</i> , <b>2017</b> , 12, e0181334	3.7	4
12	Rheumatoid arthritis: previously untreated early disease. <i>Clinical Evidence</i> , <b>2016</b> , 2016,		4
11	The intelligent use of systemic glucocorticoids in rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , <b>2014</b> , 10, 143-57	5.1	3
10	Achieving consensus on minimum data items (including core outcome domains) for a longitudinal observational cohort study in rheumatoid arthritis. <i>Rheumatology</i> , <b>2017</b> , 56, 550-555	3.9	2
9	Low dose corticosteroids in early rheumatoid arthritis. Can these drugs slow disease progression?. <i>Drugs and Aging</i> , <b>1996</b> , 8, 157-61	4.7	2
8	Item Development and Face Validity of the Rheumatoid Arthritis Patient Priorities in Pharmacological Interventions Outcome Measures. <i>Patient</i> , <b>2016</b> , 9, 103-15	3.7	

- 7 Revitalising glucocorticoids for (rheumatoid) arthritis. *Clinical Medicine*, **2010**, 10, 159-60 1.9
- 6 The use of glucocorticoids in preventing joint destruction: Comment on the review by Schett et al. *Arthritis and Rheumatism*, **2009**, 60, 1202-3; reply 1203-4
- 5 Early rheumatoid arthritis: combination therapy with disease-modifying antirheumatic drugs and low-dose glucocorticoids?. *Nature Clinical Practice Rheumatology*, **2006**, 2, 182-3
- 4 The Use of Guidelines for Managing and Treating Osteoarthritis. *Disease Management and Health Outcomes*, **1998**, 3, 131-142
- 3 Does treatment with glucocorticoids or with disease-modifying antirheumatic drugs reduce the rate of radiographic progression in rheumatoid arthritis? Comment on the article by Abu-Shakra et al. *Arthritis and Rheumatism*, **1999**, 42, 1066-7
- 2 Systemic glucocorticoids in chronic arthritis **2001**, 175-190
- 1 Systemic glucocorticoids in rheumatoid arthritis **2005**, 247-264